Nycomed's intranasal fentanyl recommended for EU marketing
This article was originally published in Scrip
Instanyl, Nycomed's intranasal formulation of fentanyl citrate, has been recommended for centralised marketing approval in the EU for the treatment of breakthrough pain in cancer patients who receive chronic opioid treatment for the management of their background pain.
You may also be interested in...
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.